Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.
Each week, we like to take a moment to boil down the biggest news from the most influential companies in the pharmaceuticals industry, and tell our viewers what that news means for you. We call that segment our Big Pharma Roundup.
In this week's installment, Johnson & Johnson's (JNJ +0.00%) fastest growing drug Zytiga was approved Monday by the FDA for a pre-chemo indication. While this was largely expected, this is a major step for the drug, as the pre-chemo indication is much bigger than the indication as a second line treatment. In this video, Motley Fool health-care analyst Brenton Flynn tells us what this means for the company and the drug from here.
Motley Fool Returns
Market-beating stocks from our flagship service.
Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 2025-08-29 13:56:54.084425.
Discounted offers are only available to new members. Stock Advisor list price is $199 per year.
Calculated by Time-Weighted Return since 2002. Volatility profiles based on trailing-three-year calculations of the standard deviation of service investment returns.
